Bizhen Lin

机构：Sinovac Biotech, Institute of Subtropical Agriculture, Fujian Academy of Agricultural Sciences

发表论文 15 篇 · 总被引 228 次 · h-index 6

代表论文

• Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial (2022 · The Lancet Infectious Diseases · 被引 93)
• Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response (2021 · Emerging Microbes & Infections · 被引 61)
• Naturally acquired HPV antibodies against subsequent homotypic infection: A large-scale prospective cohort study (2021 · The Lancet Regional Health - Western Pacific · 被引 24)
• Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages (2020 · Vaccine · 被引 14)
• Safety and immunogenicity of an Escherichia coli -produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial (2022 · Human Vaccines & Immunotherapeutics · 被引 10)
• Long-Term immunopersistence and safety of the Escherichia coli -produced HPV-16/18 bivalent vaccine in Chinese adolescent girls (2022 · Human Vaccines & Immunotherapeutics · 被引 8)